According to an analysis led by the Duke Cancer Institute, tasquinimo, an investigational prostate cancer treatment slows disease progression and may also increase survival, especially among men whose cancer has spread to the bones. This study that was published on Nov. 19, 2013, in the journal Clinical Cancer Research, shows that long-term survival and safety [...]
Now that Radium-223 Dichloride (Xofigo) has been approved by the FDA for use in men with castrate resistant prostate cancer with bone metastases we will begin to see the actual treatments happening. The next question in the process that will arise is whether or not it is safe and effective to re-treat an individual with [...]
There was a recent study to investigate the predictive value of the number of extra-spinal organs involved by metastases for survival in metastatic spinal cord compression (MSCC) from prostate cancer. This was a very small study of only 95 men irradiated with 10×3 Gy for MSCC from prostate cancer. The investigators considered seven factors: Age, [...]
Those of us with advanced prostate cancer who have used hormone therapy (ADT) often find that we are plagued with hot flashes that are detrimental to our quality of life (QOL). I believe that hot flashes are the most common side effect complained about by men who are on ADT, in the scheme of seriousness [...]
The makers of Enzalutamide (Xtandi), Astellas Pharma US, Inc and Medivation, Inc have begun a Phase 4 clinical trial known as PLATO. The study is designed to evaluate the efficacy and safety of continued treatment with enzalutamide (Xtandi) plus abiraterone acetate (Zytiga) and prednisone as compared to treatment with Zytiga and prednisone alone in men [...]